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doi:10.1016/j.ejvs.2010.08.018Abstract Objectives: To report the results of long-term follow-up of abdominal aortic aneu-
rysms (AAAs) treated with endografts more than a decade ago.
Design: Retrospective analysis of estimated long-term follow-up, mortality and morbidity in
terms of complications and re-interventions, using the KaplaneMeier survival analysis.
Materials/methods: Between March 1997 and January 2000, 61 patients with AAA (53 asymp-
tomatic, four symptomatic and three ruptured) were treated with aortic endografts. All preop-
erative, operative and follow-up data were recorded according to the EUROpean collaborators
on Stent graft Techniques for abdominal aortic Aneurysm (EUROSTAR) criteria.
Results: The primary technical success rate was 98.4%. The majority of used devices were
Vanguard (65.0%), and in a bifurcated configuration (86.7%). At 10-year follow-up, the esti-
mated cumulative follow-up rate was 82.0%; complications occurred in 74.6% of the patients
and re-interventions were required in 56.9%. The Vanguard endograft was related to a higher
incidence of re-interventions (P Z 0.012). The combined in-hospital or AAA-related mortality
rate was 5.0% at 30 days and 8.2% at a 10-year follow-up (1.8% and 5.0% in elective cases,
respectively).
Conclusions: Early abdominal endografts are associated with high incidence of complications
(74.6%) and re-interventions (56.9%) at a 10-year follow-up; however, the mortality rate
related to the procedure or aneurysm is low (5.0% in elective cases). Early endografts need
lifelong strict surveillance.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Since Parodi in 19911 and Volodos in 1986 demonstrated the
feasibility of aortic aneurysm exclusion deploying a stent
graft introduced through the femoral arteriesrgery Division, Department of Ca
4669882165, þ34932275749; fax:
ail.com (G. Mestres).
ty for Vascular Surgery. Publishe(endovascular aneurysm repair (EVAR)), different devices,
designs, configurations, delivery systems and implantation
techniques have been commercialised.rdiovascular Surgery, Thorax Institute, Hospital Clinic, C\Villarroel
þ34932275749.
d by Elsevier Ltd. All rights reserved.
Early Abdominal Aortic Endografts 723The use of first- and second-generation devices was
quickly widespread, based on good initial results; later
randomised controlled trials have confirmed these better
initial results with endovascular techniques compared with
open surgery, but follow-up was still to be done;2,3 these
early endograft devices seemed to be related to a high
incidence of complications, aortic rupture and a need for
re-interventions during follow-up.4e6
The aim of this study is to report the long-term follow-up
results of the early implanted endografts in our institution.
Materials and Methods
Between March 1997 and January 2000, 61 consecutive
patients with abdominal aortic (AAA) or aorto-iliac aneurysms
(corresponding to 40.7% of all AAA surgeries) were treated in
our institution by EVAR. Isolated iliac aneurysms, other
abdominal pathologies and thoracic lesions were excluded in
this article. During this period, the selection criteria for the
endovascular approach were based on good aortic anatomy,
high medical co-morbidities and patient preference. All
surgeries were performed by two surgeons, with the same
operative criteria. All data concerning preoperative basis and
imaging, operative findings, complications and other events
until discharge were registered prospectively following the
EUROpean collaborators on Stent graft Techniques for
abdominal aortic Aneurysm Repair (EUROSTAR) enrolment
form,7 according to the Society of Vascular Surgery/Interna-
tional Society of Cardiovascular Surgery (SVS/ISCVS) guidelines
for baseline data.8 Follow-up at the outpatient clinic was
performed at 1, 3, 6, 12, 18 and 24 months, and annually
thereafter, revising the clinical examination, abdominal 4-
plane X-ray and abdominal computed tomography (CT) angio-
gram (substituted in later years by abdominal ultrasounds);we
registered all this data using the EUROSTAR follow-up form.7
All patients were informed of the risks and benefits of
both open and endovascular surgery, and all of them
accepted the endovascular repair and signed the informed
consent form. The use of endografts was also previously
approved by the hospital ethical committee. Device selec-
tion was based on preoperative CT angiogram and pre- or
intra-operative catheter calibrated angiography measures.
We usually preferred the bifurcated devices; tube devices
were used only in particular preliminary cases, and aor-
touniiliac devices were chosen when bifurcated ones were
likely to be difficult to implant. Preoperative data are
described in Table 1.
All endovascular procedures were performed in a radi-
ology suite with aseptic conditions. Usually, routine surgical
exposure of both common femoral arteries under regional
anaesthesia was performed to device progression.
Statistical Analysis
Descriptive parameters (described as mean and range) and
frequencies from preoperative and in-hospital data were
obtained using the Statistical Package for Social Sciences
(SPSS), Version 15.0 statistical package. Time-to-event was
analysed with the KaplaneMeier survival analysis; we
calculated the mean and 95% confidence interval rates of
every follow-up event, and the estimated rates at 24, 60and 120 months (2, 5 and 10 years). Comparisons between
different groups (device used, aneurysm size and mural
thrombus implication) were made using the KaplaneMeier
survival analysis, and the statistical significant difference
was evaluated using the log rank (ManteleCox) analysis. P
value < 0.05 was considered to be statistically significant.
Results
Operative data
One of the 61 enrolled cases was aborted because of iliac
calcification (failure to complete the procedure). The tech-
nical success rate was 98.4%: as many as 60 patients were
treatedwith an endovascular graft,most of thembifurcated.
Majority of used grafts were the Vanguard device (65.0%).
Oversizing was according to the manufacturer’s instructions
for each device (usually 15%). Proximal extensions (cuffs)
were needed in four (6.7%) and additional distal extensions in
18 (30.0%) cases. Intra-operative complicationswerenoticed
in 19.7% of the cases. Intentional blocking of sidebranches
was done in eight patients (eight internal iliac arteries), and
inadvertent blocking in two (one internal iliac artery and one
accessory renal artery).
The mean hospital stay was 4.36 days, during which time
additional surgeries were not required. The hospital stay
mortality was 5.0%; there were three in-hospital deaths:
two in previous ruptured aneurysms (immediate hypo-
volaemic shock, and a delayed postoperative multi-organ
failure because of multiple visceral embolisation) and
another postoperative cardiac arrest in an elective aneu-
rysm repair. Operative and device data are described in
Tables 2 and 3.
Follow-up
Six patients were lost to follow-up (10.0%), 35 died (58.3%)
and 19 completed at least a 10-year follow-up period
(31.7%). The estimated cumulative follow-up rates at 2, 5
and 10 years were 95.6%, 93.2% and 82.0%.
At 10 years of follow-up, the estimated rate of compli-
cations was up to 74.6%; 32 patients developed at least one
complication. We noticed leg migration in 27.1%, leg kink-
ing or stenosis in 23.9% and body migration in 23.3%; the
rate of endoleaks was as high as 53.2%, mostly due to types
II and III.
Due to previously described complications, up to 56.9% of
patients required at least one reintervention, and 33.3% of
them required more than one (up to three). Endovascular
procedures were performed in all re-interventions; the most
common were leg extensions (39.4%). EVAR conversion
(deployment of a new aortouniiliac or bifurcated endograft
inside a previous one, usually due to migrations or discon-
nections not treatable with simple cuffs or extensions) was
performed in 18.8% of the series (eight patients);wedeployed
six aortouniiliac and two bifurcated devices inside previous
bifurcated (six), aortouniiliac (one) or tube (one) grafts.
However, far from being considered cured after EVAR
conversion, three of the eight patients presented later
complications during follow-up (new endoleaks in two and leg
thrombosis in one), requiring further re-interventions.
Table 1 Preoperative data (AAA Z abdominal aortic aneurysm).
N (or mean) % (or range)
Sex Men 58 95.1%
Age (years) 71.6 52e90
ASA (American society of
Anesthesiologist) classification
II 6 9.8%
III 51 83.6%
IV 4 6.6%
Co-morbiditiesa Diabetes Mellitus 13 21.3%
Tobaco use history 50 82.0%
Hypertension 53 86.9%
Hyperlipemia 30 49.2%
Obesity 21 34.4%
Cardiac disease 39 63.9%
Carotid disease 9 14.8%
Renal disease 19 31.1%
Pulmonary disease 39 63.9%
Previous laparotomy 18 29.5%
Clinical presentation Asymptomatic 54 88.6%
Symptomatic 4 6.6%
Ruptured 3 4.9%
AAA measures (mm) Infrarenal neck diameter (D2b) 23.5 16e35
Infrarenal neck length (H1) 26.4 10e52
Maximum aortic diameter (D3) 60.8 38e100
Aortic patent lumen (D3a) 39.2 20e85
Eurostar AAA
morphology classb
Aorta or aortic bifurcation (types A and B) 44 72.1%
Proximal common iliac arteries (C) 12 19.6%
One or both iliac bifurcations or external
iliac arteries (D and E)
5 8.2%
a Co-morbidities: Moderate or severe SVS/ISCVS risk-factor score;8 Obesity: Body mass index greater than 30.
b Distal involvement of the AAA. The Eurostar classification of aneurysm morphology has been described in detail by Harris et al.7
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moral bypass due to endograft leg thrombosis) and another
one required conversion to open surgery (aortofemoral
bypass surgery and explant of the previous endograft).Table 2 Operative data.
Duration of procedure (minutes)
Blood transfusion
Intra-operative complications Total
Failure to complete
Device related
Arterial
Procedure
Access or lower limb
Systemic complicati
Technical success
Blocking of sidebranches Total
Renal artery
Accessory renal arte
Unilateral Iliac arter
Bilateral iliac artery
Competition angiogram endoleaks Total
Type Ia
Type II
Type IIIThere were two cases of aortic aneurysm rupture during
follow-up in patients with a previous aortic endograft (both
with Vanguard bifurcated devices). The first case devel-
oped at 33 months of follow-up: a leg disconnection,N (or mean) % (or range)
133.9 50e360
6 9.8%
12 19.7%
the procedure 1 1.6%
4 6.6%
1 1.6%
1 1.6%
2 3.3%
ons 7 11.5%
60 98.4%
10 16.7%
0 0%
ry 1 1.7%
y 9 15.0%
0 0%
9 15.0%
5 8.3%
2 3.3%
2 3.3%
Table 3 Device properties and hospital stay complications.
N (or mean) % (or range)
Device properties
Device type Vanguard Endovascular Aortic Graft (Boston Scientific, Natick, MA) 39 65.0%
Medtronic Talent Abdominal Stent Graft (Medtronic AVE, Santa Rosa, CA) 15 25.0%
Gore Excluder AAA Endoprosthesis (W.L. Gore & Associates, Flagstaff, AZ) 2 3.3%
Lifepath AAA Endovascular Graft System (Edwards Lifesciences, Irvine, CA) 2 3.3%
AneuRx Stent Graft System (Medtronic AVE, Santa Rosa, CA) 1 1.7%
Cook Zenith AAA Endovascular Graft (Cook, Bloomington, IN) 1 1.7%
Configuration Bifurcated 52 86.7%
Aortouniiliac 5 8.3%
Tube 3 5.0%
Characteristics Proximal diameter (millimeters) 26.7 16e40
Proximal cuffs needed 4 6.7%
Additional distal extensions needed 18 30.0%
Hospital stay complications
Intensive care stay ICU requiring 43 71.7%
Mean time (hours) 5.12 2e12
Hospital stay Duration (days) 4.36 1e16
Reintervention 0 0%
Open conversion 0 0%
Mortality 3 5.0%
Early Abdominal Aortic Endografts 725promoting a massive type III endoleak and sac rupture. It
was successfully treated with an emergent iliac extension,
but it suffered a new sac rupture due to contralateral iliac
disconnection 21 months later. It was again successfully
treated with another emergent iliac extension. Conversion
to aortouniiliac graft was not possible because of inability
to progress the device through the iliac segment, and open
conversion was not considered because of extensive co-
morbidities; this patient finally died because of a new
endograft disconnection and novel aneurysm rupture 4
months later. The second case developed at 41 months of
follow-up: an aneurysm sac rupture without clear endo-
leaks; under endotension suspicion, it was successfully
treated with an emergent aortouniiliac conversion (Talent
device). Four years later, a new asymptomatic massive
distal type I endoleak without sac rupture was observed; it
was electively treated with open aortic conversion (aorto-
femoral bypass), without new major complications at a 10-
year follow-up (Figs. 1 and 2).
The majority of patients were dead at a 10-year follow-up
(an estimated rate of 61.4%), usually due to non-aneurysm or
procedure-related causes (frequently associated with
cardiac, pulmonary or oncologic diseases). Three patients
died before discharge, and another one died during follow-up
because of a ruptured aortic aneurysm; the estimated
combined in-hospital or AAA-related mortality was 8.2%
(includingdeaths during in-hospital stay, related toprocedure
or aortic aneurysm during follow-up). However, two of the in-
hospital deaths had preoperative ruptured aneurysms;
therefore, selecting the elective cases (non-ruptured AAA, 57
cases), the combined mortality at a 30-day and a 10-year
follow-upwas lower (1.8% and 5.0%, respectively). Details are
described in Table 4 and Fig. 3.
Mural thrombus within the inner wall of the endograft
was seen in 16 patients at the end of follow-up (estimatedrates at 2, 5 and 10 years: 26.7%, 29.4% and 34.5%). It
appeared early (in 81% of the patients during the first year),
and a slightly higher but non-significant difference in a 10-
year estimated rate of graft or leg thrombosis was seen
(7.4% vs. 15.6%, P Z 0.403).
Vanguard endografts, compared with other devices,
showed a higher but non-significant estimated rate of
complications (86.8% vs. 62.9%, P Z 0.455) and a signifi-
cantly higher rate of re-interventions (84.2% vs. 26.3%,
PZ 0.012). Small aneurysms (diameter under 5.5 cm) were
not related to a lower complication or reintervention rates
(P Z 0.527 and 0.362, respectively).Discussion
Endovascular treatment of AAAs with first- and second-
generation endografts has good intra-operative results. As
other publications have reported,4e6,9e11 a high technical
success rate can be achieved (98.4%) with a low rate of
intra-operative and in-hospital complications (19.7%, most
of them solved intra-operatively).
The in-hospital mortality was high (three cases: 5.0%),
probably due to patient selection; two of the in-hospital
deaths had preoperative ruptured aneurysms, and open or
endovascular treatment in this group of patients has been
related to obvious worst results.12e15 The in-hospital
mortality for elective cases was 1.8%. Taking into account
this detail, these results can be compared with other
published data (first 30 days’ mortality rates in Endovas-
cular aneurysm repair versus open repair in patients with
abdominal aortic aneurysm (EVAR Trial 1): 4.64% for open
surgery vs. 1.66% for EVAR).3
The long-term follow-up rate was 82.0% (six patients lost
to follow-up), an acceptable percentage taking into
Figure 1 A) Control angiography after a bifurcated Vanguard device implantation. B) Right leg disconnection and distal body
migration 33 months later, promoting a massive type III endoleak and aneurysm rupture; it was successfully treated with a right
iliac extension and a proximal cuff. C) New left leg disconnection 21 months later, D) promoting again aneurysm pressurization and
sac rupture; it was treated with a new iliac extension.
726 G. Mestres et al.account the age and co-morbidities of these patients, and
near to other long-term series.5 As in other articles,5,6,9
during the 10-year follow-up period, a high incidence of
complications occurred (74.6%). Endograft leg migration
and endoleaks were the most common complications (27.1%
and 53.2%, respectively). It confirms the instability and
structural defects of these early endografts. That the
Vanguard endografts (the most commonly used device in
this series) failed to attach to the aortic neck, the thin
Dacron fabric was eroded by the stents, sutures linking the
rows of the stents broke and the short body and short
overlapping zones led to leg migration, disconnection and
subsequent endoleaks has been already published.5,16,17
Due to the enormous rate of complications, a large
number of patients required re-interventions during follow-
up (up to 56.9%), near to other series.5,18,19 Given the high
burden of migration and endoleaks, proximal and distal
extensions were commonly required (8.7% and 39.4%). We
tried to avoid open conversion, and when repair of the
actual endograft was not possible or was rejected, endo-
vascular conversion to a new endograft was performed, butFigure 2 A) Control angiography after a bifurcated Vanguard de
months later, C) successfully treated with a left iliac extension. D) A
later; conversion to aortouniiliac device was performed. E) Massi
electively treated with open aortic conversion.3 of these 8 conversions required further re-interventions.
Reinforcing the already published data,20 mural thrombus
appeared early in the follow-up (in 81% during the first
year) inside the endograft, but it was not significantly
related to a higher incidence of thrombotic events.
As we expected, at the 10-year follow-up, Vanguard
endografts showed worst results due to a higher rate of re-
interventions, probably related to their design defects. The
necessary learning curves in engineering will provide in the
future, and surely still in the present, better and more
durable devices.
Majority of patients were dead at the 10-year follow-up,
but the estimated combined in-hospital or AAA-related
mortality at a 30-day and a 10-year follow-up was only 5.0%
and 8.2%, respectively (1.8% and 5.0% in elective cases).
In conclusion, early abdominal endografts are associated
with a high incidence of complications and re-interventions
at long-term follow-up, and lifelong strict surveillance is
mandatory for these early devices. However, most of these
complications can be repaired with endovascular tech-
niques, reaching a low final aneurysm-related mortality.vice implantation. B) Asymptomatic left leg disconnection 37
neurysm enlargement and rupture due to endotension 4 months
ve distal type I endoleak was confirmed 4 years later; it was
Table 4 Complications, re-interventions and mortality during follow-up (percentage and typical error; estimated data
provided by KaplaneMeier survival analysis).
2 years TE 5 years TE 10 years TE
Complications 23.0% 0.059 62.9% 0.076 74.6% 0.071
Kinking or stenosis 4.7% 0.033 15.8% 0.060 23.9% 0.077
Body migration 4.0% 0.028 15.1% 0.058 23.3% 0.760
Leg migration 0% 0 22.3% 0.070 27.1% 0.081
Endoleak 13.1% 0.047 42.4% 0.079 53.2% 0.086
I 4.4% 0.031 15.8% 0.060 20.1% 0.070
II 6.0% 0.033 20.6% 0.067 30.0% 0.086
III 3.3% 0.023 24.8% 0.075 30.6% 0.089
IV or Endotension 0% 0 3.4% 0.034 3.4% 0.034
Thrombosis 3.8% 0.027 9.8% 0.048 9.8% 0.048
Stent fracture 6.1% 0.035 12.3% 0.054 12.3% 0.054
AAA rupture 0% 0 5.3% 0.036 5.3% 0.036
Distal iliac aneurysms 0% 0 0% 0 3.7% 0.036
Re-interventions 8.0% 0.039 42.2% 0.08 56.9% 0.088
Endovascular 8.0% 0.039 42.2% 0.080 56.9% 0.088
Proximal cuff 1.8% 0.018 4.4% 0.031 8.7% 0.052
Leg extension 0% 0 22.4% 0.071 39.4% 0.094
Thrombolisys or PTA 0% 0 5.8% 0.040 5.8% 0.040
Embolisation 0% 0 7.8% 0.043 7.8% 0.043
EVAR conversiona 4.4% 0.022 18.8% 0.065 18.8% 0.065
Open reinterventionb 2.3% 0.023 2.3% 0.023 2.3% 0.023
Conversion to open surgeryc 0% 0 0% 0 5.3% 0.051
Mortality 28.6% 0.059 48.2% 0.066 61.4% 0.065
Combined in-hospital or AAA-
related mortalityd
5.0% 0.028 8.2% 0.041 8.2% 0.041
Combined in-hospital or AAA-
related mortality in elective
cases
1.8% 0.017 5.0% 0.036 5.0% 0.036
a EVAR conversion: deployment of a new aortouniiliac or bifurcated endograft inside of a previous one.
b Open reintervention: femorofemoral bypass due to endograft leg thrombosis.
c Conversion to open surgery: aortofemoral bypass surgery, and explant of the previous endograft.
d Combined in-hospital or AAA-related mortality: deaths during in-hospital stay, related to procedure or aortic aneurysm, in all cases
(asymptomatic, symptomatic and ruptured AAA; n Z 60) and elective cases (non-ruptured AAA; n Z 57).
Figure 3 KaplaneMeier postoperative survival analysis at 10 years follow-up: A) Freedom from complication, and B) freedom
from reintervention.
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